Causeway Capital Management LLC Grows Stake in GSK PLC Sponsored ADR $GSK

Key Points

• Causeway Capital Management LLC increased its stake in GSK PLC Sponsored ADR by 2.9%, holding approximately $42.92 million worth of shares, which makes up 0.9% of its investment portfolio.
• GSK reported earnings of $1.23 per share, surpassing estimates, with quarterly revenue reaching $10.64 billion, indicating a year-over-year increase of 1.3%.
• The company announced a quarterly dividend of $0.4206 per share, yielding 4.2%, despite a dividend payout ratio of 77.78%.

Causeway Capital Management LLC increased its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 2.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,107,923 shares of the pharmaceutical company's stock after acquiring an additional 31,343 shares during the period. GSK comprises 0.9% of Causeway Capital Management LLC's investment portfolio, making the stock its 29th biggest holding. Causeway Capital Management LLC owned 0.05% of GSK worth $42,921,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. HHM Wealth Advisors LLC raised its holdings in shares of GSK by 222.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after acquiring an additional 460 shares during the last quarter. Costello Asset Management INC acquired a new stake in shares of GSK in the 1st quarter worth about $31,000. Richardson Financial Services Inc. raised its holdings in shares of GSK by 127.9% in the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after acquiring an additional 472 shares during the last quarter. Olde Wealth Management LLC bought a new position in shares of GSK during the 1st quarter worth approximately $36,000. Finally, Cary Street Partners Investment Advisory LLC lifted its position in shares of GSK by 525.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after buying an additional 852 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on GSK. Wall Street Zen raised shares of GSK from a "hold" rating to a "buy" rating in a research report on Sunday, August 3rd. Berenberg Bank reissued a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Six research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, GSK has an average rating of "Reduce" and an average target price of $37.38.

GSK Stock Performance

Shares of GSK stock traded up $0.24 during trading hours on Friday, hitting $39.68. 3,590,956 shares of the company were exchanged, compared to its average volume of 3,181,567. The firm has a fifty day simple moving average of $38.40 and a 200 day simple moving average of $38.24. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. GSK PLC Sponsored ADR has a 52-week low of $31.72 and a 52-week high of $44.26. The stock has a market capitalization of $80.82 billion, a price-to-earnings ratio of 18.37, a P/E/G ratio of 1.72 and a beta of 0.51.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The business had revenue of $10.64 billion during the quarter, compared to analyst estimates of $7.92 billion. During the same period in the previous year, the business earned $0.43 EPS. GSK's revenue was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Research analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be paid a $0.4206 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date is Friday, August 15th. GSK's payout ratio is currently 77.78%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.